| Quarter | Prior | Estimate | Actual | Surprise | |
|---|---|---|---|---|---|
| Q3 2019 Pre-Market | EPS: REV: | 0.49 190.829M | |||
| Q2 2019 Pre-Market | EPS: REV: | 0.67 204.276M | |||
| Q1 2019 Pre-Market | EPS: REV: | 0.72 202.68M | |||
| Q4 2018 Pre-Market | EPS: REV: | 0.72 177.402M | 1.46 285.13M | 1.43 292.566M | -2.05% 2.61% |
| Q3 2018 Pre-Market | EPS: REV: | 0.82 191.411M | 0.51 191.06M | 0.49 190.829M | -3.92% -0.12% |
| Q2 2018 Pre-Market | EPS: REV: | 0.03 223.534M | 0.54 189.86M | 0.67 204.276M | 24.07% 7.59% |
| Q1 2018 Pre-Market | EPS: REV: | 0.58 204.273M | 0.53 184.76M | 0.72 202.68M | 35.85% 9.7% |
| Q4 2017 Pre-Market | EPS: REV: | 0.9 204.653M | 0.58 188.61M | 0.72 177.402M | 24.14% -5.94% |
| Q3 2017 Pre-Market | EPS: REV: | 0.38 194.652M | 0.67 186.88M | 0.82 191.411M | 22.39% 2.42% |
| Q2 2017 Pre-Market | EPS: REV: | 0.31 189.988M | 0.65 206.3M | 0.03 223.534M | -95.38% 8.35% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- 'We See Room For Further Outperformance': CyberArk Analysts Bullish After Q4 Earnings Beat
- KeyBanc: Diebold's New CEO Executing Well, But Long-Term Growth Remains A Concern
- Dana Inc. Beats Q4 And Full-Year 2018 Expectations
- Analysts Aren't Cutting CBS Despite Earnings Miss
- The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings